Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2021

01-10-2021 | Climate Change | Commentary

Logistics management provides greater efficiency, governance and compliance

Authors: Francesco Ferrara, Priscilla Santilli, Antonio Vitiello, Giampiero Forte, Vilma D’Aiuto

Published in: International Journal of Clinical Pharmacy | Issue 5/2021

Login to get access

Abstract

During the 2020 Congress of the Italian Society of Hospital Pharmacy (Sifo 2020), there was a heated debate about whether it is more convenient to dispense healthcare directly in hospitals and public facilities, or indirectly, through the use of external private pharmacies. The former solution is called “direct dispensing” (DD), while the latter is called “dispensing on commission” (DPC). The strengths and advantages of DD over DPC are many: greater therapeutic appropriateness due to direct control of treatment plans, cost savings from external commissions, and greater clinical sharing of treatment by all healthcare personnel. The main weakness is the organization of a complex warehouse. As the number of chronic patients and advanced therapies increases, direct care requires a new structure and logistics system to manage large administrative, accounting, and information flows. The purpose of this article is to compare the two logistic models implemented in Italy in order to structure a computerized model that can increase the efficiency of the National Health System (NHS).
Literature
2.
go back to reference Ciacca A. Malattie Croniche: riorganizzazione dei percorsi di cura e dell’assistenza farmaceutica territoriale. Boll SIFO 2020;66(6):346–354. Ciacca A. Malattie Croniche: riorganizzazione dei percorsi di cura e dell’assistenza farmaceutica territoriale. Boll SIFO 2020;66(6):346–354.
4.
go back to reference Ferrara F, Santilli P, Bartolini L, Vitiello A, Pennacchia A, Di Croce S, et al. L’importanza del magazzino logistico in periodo di pandemia: l’esperienza dell’USL Umbria 1 durante covid-19. Recenti Prog Med. 2021;112(3):219–24.PubMed Ferrara F, Santilli P, Bartolini L, Vitiello A, Pennacchia A, Di Croce S, et al. L’importanza del magazzino logistico in periodo di pandemia: l’esperienza dell’USL Umbria 1 durante covid-19. Recenti Prog Med. 2021;112(3):219–24.PubMed
5.
go back to reference Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia? Ital J Med. 2020;14(2):88–94. Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia? Ital J Med. 2020;14(2):88–94.
6.
go back to reference Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;1–4. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;1–4.
7.
go back to reference Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul;27:bmjebm–2020. Vitiello A, La Porta R, Ferrara F. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul;27:bmjebm–2020.
8.
go back to reference Ferrara F, Porta R, Santilli P, D’Aiuto V, Vitiello A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020;52(5):441–2.CrossRef Ferrara F, Porta R, Santilli P, D’Aiuto V, Vitiello A. Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol. 2020;52(5):441–2.CrossRef
9.
go back to reference Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;S1359-6446(21)00037 – 4. Vitiello A, Pelliccia C, Ferrara F. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug Discov Today. 2021;S1359-6446(21)00037 – 4.
10.
go back to reference Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021;147:110486.CrossRef Vitiello A, La Porta R, Ferrara F. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021;147:110486.CrossRef
11.
go back to reference Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021;1–5. Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021;1–5.
12.
go back to reference Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020;1–2. Vitiello A, Ferrara F. Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. 2020;1–2.
13.
go back to reference Vitiello A, Ferrara F, Porta R. Remdesivir. and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;1–2. Vitiello A, Ferrara F, Porta R. Remdesivir. and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;1–2.
14.
go back to reference Ferrara F, Porta R, D’Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;1–2. Ferrara F, Porta R, D’Aiuto V, Vitiello A. Remdesivir and COVID-19. Ir J Med Sci. 2020;1–2.
15.
go back to reference Vitiello A, La Porta R, D’Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;S0198-8859(21)00014 – 8. Vitiello A, La Porta R, D’Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;S0198-8859(21)00014 – 8.
16.
go back to reference Ferrara F, Vitiello A. Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. 2020;15:1.CrossRef Ferrara F, Vitiello A. Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. 2020;15:1.CrossRef
17.
go back to reference Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;262:118510.CrossRef Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020;262:118510.CrossRef
18.
go back to reference Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021;156:105579.CrossRef Vitiello A, Ferrara F. Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci. 2021;156:105579.CrossRef
19.
go back to reference Vitiello A, La Porta R, Ferrara F. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020;bmjebm-2020-111589. Vitiello A, La Porta R, Ferrara F. Correlation between the use of statins and COVID-19: what do we know? BMJ Evid Based Med. 2020;bmjebm-2020-111589.
20.
go back to reference Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114–5. Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Ital J Med. 2020;14(2):114–5.
Metadata
Title
Logistics management provides greater efficiency, governance and compliance
Authors
Francesco Ferrara
Priscilla Santilli
Antonio Vitiello
Giampiero Forte
Vilma D’Aiuto
Publication date
01-10-2021
Publisher
Springer International Publishing
Keyword
Climate Change
Published in
International Journal of Clinical Pharmacy / Issue 5/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-021-01283-6

Other articles of this Issue 5/2021

International Journal of Clinical Pharmacy 5/2021 Go to the issue